At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,041 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Korean Post-marketing Surveillance for Xeljanz(Registered) in Rheumatoid Arthritis and Psoriatic Arthritis Patients
In Brief
An observational study for Rheumatoid Arthritis and Psoriatic Arthritis. Completed, enrolled 1,041 participants across 49 sites.
Detailed Summary
The objective of this study is to identify any problems and questions with respect to the safety and efficacy of Xeljanz during the post-marketing period as required by the regulation of MFDS.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Psoriatic Arthritis
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedDec 2016
Primary CompletionJun 2022
TodayJul 2026
First PostedDec 6, 2016
Enrollment StartMay 13, 2016
Primary CompletionJun 9, 2022
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 9.6 years ago